Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies for neurologically mediated conditions, primarily focusing on chronic cough. Founded in 2011, the company's mission is to improve the lives of patients suffering from these debilitating conditions. Its headquarters are located in New Haven, Connecticut, at 195 Church Street, 16th Floor. [4, 6, 10, 18, 22, 24, 26]

The company's key product is Haduvio™ (oral nalbuphine extended-release), an investigational therapy. [3, 5, 6, 10, 12, 13, 16, 19, 22, 23, 24, 25, 26] Haduvio operates as a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist (KAMA), targeting opioid receptors involved in the central and peripheral cough reflex arc. [12, 16, 25] Trevi Therapeutics is developing Haduvio for chronic cough associated with Idiopathic Pulmonary Fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), areas where there are currently no FDA-approved therapies. [3, 6, 10, 12, 13, 16, 19, 22, 23, 25]

In recent news, Trevi Therapeutics reported its year-end 2025 financial results and clinical updates on March 17, 2026, projecting a cash runway into 2028. [3, 20] The company achieved FDA alignment following an End-of-Phase 2 meeting for IPF-related chronic cough and plans to initiate two Phase 3 trials in Q2 and H2 2026, alongside Phase 2b trials for RCC and non-IPF ILD. [3, 9, 12, 20, 25] In April 2026, Trevi Therapeutics completed an underwritten public offering, raising approximately $173 million in gross proceeds. [2, 3] Jennifer Good serves as the Co-Founder, President & CEO, with David Hastings appointed as Chief Financial Officer effective January 6, 2026. [6, 9, 11, 24, 26] The company is positioned as a clinical-stage biopharmaceutical firm focused on addressing significant unmet medical needs with its lead candidate, Haduvio. [25, 26]